不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Beckman Coulter 收购Diagnostic Systems Laboratories, Inc.

Beckman Coulter 收购Diagnostic Systems Laboratories, Inc.

互联网2013年5月17日 14:51 点击:1918

2005年10月7日

Beckman Coulter to Acquire Diagnostic Systems Laboratories, Inc.

Company Seeks to Gain Leadership in Specialty Endocrine Testing

FULLERTON, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc.
 (NYSE:   BEC) today announced that it has signed an agreement to acquire all of
 the stock of Diagnostic Systems Laboratories Corporation (DSL) of Webster,
 Texas, a leading provider of specialty immunoassays including proprietary
 technology for reproductive endocrinology and cardiovascular risk assessment.
 Subject to customary closing conditions, the acquisition is expected to close
 in mid-October.  The acquisition is presently estimated to be $0.01 dilutive
 to Beckman Coulter's fourth quarter EPS and $0.06 dilutive in 2006 becoming
 accretive to earnings in the fourth quarter of 2006.
      (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )
     "Coupling DSL's expertise and proprietary tests with Beckman Coulter's
 industry leading immunoassay platforms should be a winning combination," said
 Michael Whelan, group vice president of Beckman Coulter's immunoassay
 business.  "DSL is a mature organization with significant scientific and
 clinical collaboration skills.  Together we aim to quickly broaden our
 immunoassay menu and strategically advance our already successful immunoassay
 franchise."
     With 2004 sales of approximately $34 million, DSL competes in the
 specialty endocrinology segment of the immunoassay market.  DSL markets three
 proprietary reproductive endocrinology tests, including Inhibin A and B, and
 anti-Mullerian hormone.  In addition, DSL holds exclusive rights to PAPP-A, a
 marker being evaluated for cardiovascular risk assessment.  Recently growing
 at about 15 percent per year, specialty endocrinology makes up about 10
 percent of the $5 billion immunoassay market.
     "By joining Beckman Coulter and taking advantage of their established
 infrastructure, we believe we can boost our position in specialty immunoassay
 testing and enable our group to reach its full potential in the marketplace,"
 said Gopal Savjani, president and founder of Diagnostic Systems Laboratories.
     DSL has a proven history of collaboration with clinical research leaders
 to identify new and innovative immunoassays to improve patient care.  DSL has
 successfully combined these relationships with a rapid product development
 process to quickly deliver novel tests to the pharmaceutical and life science
 research community as well as the traditional clinical laboratory.  DSL
 provides products in multiple formats and methodologies to meet a diverse
 variety of testing needs.
 
     Beckman Coulter, Inc. is a leading manufacturer of biomedical testing
 instrument systems, tests and supplies that simplify and automate laboratory
 processes.  Spanning the biomedical testing continuum -- from pioneering
 medical research and clinical trials to laboratory diagnostics and point-of-
 care testing -- Beckman Coulter's 200,000 installed systems provide essential
 biomedical information to enhance health care around the world.  The company,
 based in Fullerton, Calif., reported 2004 annual sales of $2.4 billion with 64
 percent of this amount generated by recurring revenue from supplies, test kits
 and services.  For more information, visit www.beckmancoulter.com.
 
     Safe Harbor Statement
     This press release contains forward-looking statements, including
 statements regarding the anticipated closing of the above-described
 acquisition, the effect of the acquisition on Beckman Coulter's EPS, and the
 advancement of Beckman Coulter's immunoassay business.  These statements are
 based on current expectations, forecasts and assumptions.  Actual results
 could differ materially from those anticipated by these forward-looking
 statements as a result of a number of factors, some of which may be beyond the
 company's control.  Among other things, these factors include the risk that
 the closing conditions to the acquisition will not be satisfied and the
 acquisition will not be completed, the possibility the company will not be
 able to transfer DSL assays to its Access(R) platform as anticipated, and the
 possibility that the Company's financial results will be different from those
 anticipated when the effect on EPS was calculated.  For a further list and
 description of risks and uncertainties associated with the Company's business,
 see the reports filed by Beckman Coulter with the Securities and Exchange
 Commission, including Beckman Coulter's most recent annual report on Form 10-
 K.  Beckman Coulter disclaims any intention or obligation to update or revise
 any forward-looking statements, whether as a result of new information, future
 events or otherwise, except as required by law.
 
      Contacts:
      Jeanie Herbert
      (714) 773-7620
      Investor Relations
 
      Anne M. Warde
      (714) 773-7655
      amwarde@beckman.com
      Media Relations
 
 

SOURCE Beckman Coulter, Inc.
(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图